Journal article

IgG against Plasmodium falciparum variant surface antigens and growth inhibitory antibodies in Mozambican children receiving intermittent preventive treatment with sulfadoxine-pyrimethamine

Diana Quelhas, Alfons Jimenez, Llorenc Quinto, Elisa Serra-Casas, Alfredo Mayor, Pau Cistero, Laura Puyol, Danny W Wilson, Jack S Richards, Tacilta Nhampossa, Eusebio Macete, Pedro Aide, Inacio Mandomando, Sergi Sanz, John J Aponte, Pedro L Alonso, James G Beeson, Clara Menendez, Carlota Dobano

Immunobiology | ELSEVIER GMBH | Published : 2011

Grants

Awarded by Bill and Melinda Gates Foundation


Awarded by Banco de Bilbao, Vizcaya, Argentaria Foundation


Awarded by Ministerio de Ciencia e Innovacion


Awarded by WHO/TDR


Awarded by Institut de Salud Carlos III


Funding Acknowledgements

We are grateful to the study children and their mothers and families, and the staff at the Manhica District Hospital. We thank Joe Campo, Cleofe Romagosa, Gerardo Cabrera, Lazar Quimice, Nelito Jose, Ana Rosa Manhica, and Joanne Chesson for technical support. We thank Dr. C. Chitnis (ICGEB, New Delhi) for providing us with the R29 parasite line and Dr. A. Cortes (IRB, Barcelona) for providing us with the E8B parasite line. We also thank Robin Anders and Mick Foley (WEHI, Melbourne) for allowing the use of the 1F9 monoclonal antibody. This work was supported by the Bill and Melinda Gates Foundation (grant IPTi103-0) and the Banco de Bilbao, Vizcaya, Argentaria Foundation (grant BBVA 02-0). CD is supported by the Ministerio de Ciencia e Innovacion (RYC-2008-02631), DQ was supported by WHO/TDR (grant OD/TS-07-00017), AM was supported by Institut de Salud Carlos III (CP-04/00220), and JGB, JSR, and DWW were supported by the National Health and Medical Research Council of Australia. The Centro de Investigacao em Saude da Manhica receives core support funding from the Spanish Agency for International Cooperation and Development (AECID).